摘要
目的通过对恶性肿瘤患者化疗期间联合应用康艾注射液,验证该药对肿瘤患者生活质量(quality of life,QOL)的提高作用。方法采用配对分组法,比较两组的疗效。按照新药Ⅲ期临床的观察方案进行严密观察。结果康艾注射液联合化疗能够改善肿瘤患者的QOL,防止化疗期间的体重下降。还能降低乏力、食欲减退、失眠及呕吐等不良反应的发生率,对骨髓的造血功能也表现出很好的保护作用。此外,该药还可提高NK细胞和T淋巴细胞亚群的活性。结论康艾注射液对肿瘤化疗期间的QOL具有明显地提高作用,不但能够减少化疗的不良反应,而且还能增强患者的抗肿瘤免疫。
Objective： To study the improvement of quality of life from Kang＇ai injection in patients undergoing chemotherapy, patients with advanced cancers were received chemotherapy in combination with or without Kang＇ai injection. Methods： Using matched-pairs group procedure, therapeutic effects of the two groups were compared. The experiment was carried out according to the principle of new drug Ⅲ stage clinical experiment. Results： Compared with chemotherapy group, chemotherapy in combination with Kang＇ai injection could improve the patients＇ quality of life and prevent patients＇ body weight loss. Chemotherapy combining with Kang＇ai injection could obviously reduce incidence rates of hypodynamia, anorexia, insomnia and emesia, and showed good protection of the bone marrow hematopoiesis function. Moreover, the activities of NK cells and T lymphocyte were also boosted by Kang＇ai injection. Conclusion： Kang＇ai injection can obviously improve the quality of life in patients undergoing chemotherapy, which can not only reduce the adverse reactions of chemotherapy, but also enhance the anti-tumor immunity of patients.
出处
《井冈山医专学报》
2007年第2期31-33,共3页
Journal of Jinggangshan Medical College
